Treatment of anxiety with eszopiclone
AssigneeSepracor Inc.
InventorsSeth C. Hopkins, Mark A. Varney, Tushar Misra, Gary Maier, Judy Caron, Randall S. Wagner
Life of this patent
Estimating the term…
Abstract
The present disclosure provides a unit dosage form with an anxiolytic dosage of zopiclone particularly eszopiclone. Also provided is a method for treatment or prophylaxis of anxiety using a subsedative dosage of zopiclone particularly eszopiclone.
Claims69
A unit dosage form comprising up to 0.9 mg of a compound having the structure:
- or a pharmaceutically acceptable salt, solvate, hydrate, polymorph, or prodrug thereof.
A modified unit dosage form comprising a compound having the structure:
- or a pharmaceutically acceptable salt, solvate, hydrate, polymorph, or prodrug thereof,
- wherein the unit dosage form has an AUC of at least 120 percent greater than a reference eszopiclone formulation.
A unit dosage form comprising a compound having the structure:
- or a pharmaceutically acceptable salt, solvate, hydrate, polymorph, or prodrug thereof,
- said compound being present in said dosage form in an amount or in a sustained release component effective to achieve a maximum plasma concentration (Cmax) insufficient to induce moderate sedation in a subject to which said unit dosage form is administered.
53-60. (canceled)
A method of inducing anxiolysis in a subject in need thereof, said method comprising, administering to said subject a unit dosage form comprising an amount of a compound having the structure:
- sufficient to induce anxiolysis.
(canceled)
69-72. (canceled)
A method of inducing anxiolysis in a subject in need thereof, said method comprising, administering to said subject a unit dosage form comprising up to 0.9 mg of a compound having the structure:
- or a pharmaceutically acceptable salt, solvate, hydrate, polymorph, or prodrug thereof.
A method of inducing anxiolysis in a subject in need thereof, said method comprising, administering to said subject a modified dosage form comprising a compound having the structure:
- or a pharmaceutically acceptable salt, solvate, hydrate, polymorph, or prodrug thereof,
- wherein the dosage form has an AUC of at least 120 percent greater than a reference eszopiclone formulation.
A method of inducing anxiolysis in a subject in need thereof, said method comprising, administering to said subject a modified dosage form comprising a compound having the structure:
- or a pharmaceutically acceptable salt, solvate, hydrate, polymorph, or prodrug thereof,
- said compound being present in said dosage form in an amount or in a sustained release component effective to achieve a maximum plasma concentration (Cmax) insufficient to induce moderate sedation in a subject to which said unit dosage form is administered.
A method of inducing anxiolysis in a subject in need thereof, said method comprising, administering to said subject a unit dosage form comprising a compound having the structure:
- said unit dosage form comprising said compound in a sustained release component of said formulation in an amount effective to achieve a maximum plasma concentration (Cmax) insufficient to induce moderate sedation in a subject to which said unit dosage form is administered for a period of at least 6 hours.
A method of inducing anxiolysis in a subject in need thereof, said method comprising, administering to said subject a compound having the structure:
- such that a plasma concentration of said compound is sufficient to induce anxiolysis in said subject for at least about 6 hours and a maximum plasma concentration (Cmax) is insufficient to moderately sedate said subject for greater than 1 hour.
78-81. (canceled)
Dependencies are inferred from the claim text.